AliveCor’s SEARCH-AF trial results: atrial fibrillation was identified in 1.5% of 1,000 customers
The study has also found that the incremental cost-effectiveness ratio was just over $4,000 for an increase of one Quality Adjusted Life Year.
AliveCor aims to provide medical professionals, patients, and consumers worldwide with mobile-powered devices, data, and analysis to identify, prevent, and manage life-altering diseases from anywhere in the world. As a first offering, AliveCor has developed a clinical-quality, low-cost mobile ECG device, which enables patients to monitor their heart health anywhere, at any time, and provides physicians with an additional heart health assessment tool. AliveCor’s mobile ECG device is designed to work in conjunction with a variety of mobile platforms, including iPhone, iPad, and Android devices.